Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography

Annals of Internal Medicine

Volumn 139, Issue 12, 2003, Pages 1018-1033

  McNamara, Robert L ^a   Tamariz, Leonardo J ^b   Segal, Jodi B ^b   Bass, Eric B ^b  

^a YALE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CALCIUM CHANNEL BLOCKING AGENT; CELIPROLOL; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; INDOBUFEN; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; NADOLOL; PINDOLOL; PROPAFENONE; QUINIDINE; SOTALOL; TIMOLOL; VERAPAMIL; WARFARIN; XAMOTEROL;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVERSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RATE CONTROL; HEART RHYTHM; HEART RHYTHM CONTROL; HEART VENTRICLE ARRHYTHMIA; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; THORAX PAIN; THROMBOEMBOLISM; TORSADE DES POINTES; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 0345890414     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-12-200312160-00012     Document Type: Review

References (215)

1. Bialy D, Lehmann MH, Schumacher DN, Steinman RT, Meissner MD. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation [Abstract]. J Am Coll Cardiol. 1992;19:41A.
2. Ostrander LD Jr, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic Findings among the Adult Population of a Total Natural Community, Tecumseh, Michigan. Circulation. 1965;31:888-98. [PMID: 14297523]
3. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet. 1987;1:526-9. [PMID: 2881082]
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8. [PMID: 1866765]
5. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236-41. [PMID: 8037127]
6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-5. [PMID: 11343485]
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147: 1561-4. [PMID: 3632164]
8. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476-84. [PMID: 7733127]
9. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-61. [PMID: 9337224]
10. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J. 1983;106:389-96. [PMID: 6869222]
11. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA. 1985;254:3449-53. [PMID: 4068186]
12. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med. 1987;317:669-74. [PMID: 3627174]
13. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973-7. [PMID: 570666]
14. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147: 1561-4. [PMID: 3632164]
15. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation. 1999; 99:3028-35. [PMID: 10368121]
16. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000;35:183-7. [PMID: 10636278]
17. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol. 1994;74:826-9. [PMID: 7942563]
18. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156: 1829-36. [PMID: 8790077]
19. Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320:1380-4. [PMID: 10818030]
20. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-66. [PMID: 11583910]
21. McNamara RL, Bass EB, Miller MR, Segal JB, Goodman SN, Kim NL, et al. Evidence Report on Management of New Onset Atrial Fibrillation. Agency for Healthcare Research and Quality publication no. AHRQ 01-E026. Rockville, MD: Agency for Healthcare Research and Quality; January 2001.
22. Deeks JJ, Altman DG, Bradbum MJ. Statistical methods for examining and combining results from several studies in meta-analysis. In: Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Books; 2001.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
24. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. [PMID: 12466506]
25. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40. [PMID: 12466507]
26. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-94. [PMID: 11117910]
27. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-11. [PMID: 2233931]
28. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-62. [PMID: 7901582]
29. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84:527-39. [PMID: 1860198]
30. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-91. [PMID: 7907677]
31. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-8. [PMID: 8782752]
32. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-9. [PMID: 2563096]
33. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-21. [PMID: 9679792]
34. Harenberg J, Weuster B, Pfitzer M, Dempfle CE, Stehle G, Kubler W, et al. Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin. Semin Thromb Hemost. 1993;19 Suppl 1: 116-21. [PMID: 8395713]
35. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke. 1997;28:1015-21. [PMID: 9158644]
36. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-12. [PMID: 1406859]
37. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-55. [PMID: 1856403]
38. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319:958-64. [PMID: 10514159]
39. Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, et al. EfFectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 1998;82: 433-7. [PMID: 9723629]
40. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J. 1999;138:137-43. [PMID: 10385777]
41. Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev. 2001;(1):CD001938. [PMID: 11279741]
42. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med. 2000;15:56-67. [PMID: 10632835]
43. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817-21. [PMID: 10753981]
44. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992;116:6-12. [PMID: 1727097]
45. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998; 158:1316-20. [PMID: 9645825]
46. Leung DY, Davidson PM, Cranney GB, Walsh WF. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol. 1997;79:626-9. [PMID: 9068521]
47. Stollberger C, Chnupa P, Kronik G, Brainin M, Finsterer J, Schneider B, et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. Ann Intern Med. 1998;128:630-8. [PMID: 9537936]
48. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med. 1998;128:639-47. [PMID: 9537937]
49. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;31:1622-6. [PMID: 9626843]
50. Jones EF, Calafiore P, McNeil JJ, Tonkin AM, Donnan GA. Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke. Am J Cardiol. 1996;78:425-9. [PMID: 8752187]
51. Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1994;24:755-62. [PMID: 8077549]
52. Lewis RV, Laing E, Moreland TA, Service E, McDevitt DG. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J. 1988;9:279-83. [PMID: 3289931]
53. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med. 1987;106:503-6. [PMID: 3548521]
54. Wong CK, Lau CP, Leung WH, Cheng CH. Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol. 1990;66:1212-5. [PMID: 2239725]
55. Jordaens L, Trouerbach J, Calle P, Tavernier R, Derycke E, Vertongen P, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J. 1997;18:643-8. [PMID: 9129896]
56. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J. 1997; 18:649-54. [PMID: 9129897]
57. Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol. 1995;75:88-90. [PMID: 7801876]
58. Ang EL, Chan WL, Cleland JG, Moore D, Krikler SJ, Alexander ND, et al. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J. 1990;64:256-60. [PMID: 1977430]
59. Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pedersen WR, Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol. 1994;74:884-9. [PMID: 7977118]
60. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18:891-7. [PMID: 1894861]
61. Salerno DM, Dias VC, Kleiger RE, Tschida VH, Sung RJ, Sami M, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Dildazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1989;63:1046-51. [PMID: 2650517]
62. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol. 1990;16:86-90. [PMID: 2358610]
63. Lundstrom T, Moor E, Ryden L. Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation. Am Heart J. 1992; 124:917-23. [PMID: 1356311]
64. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1989;13:1-6. [PMID: 2468920]
65. Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol. 1983;52:1197-201. [PMID: 6359848]
66. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med. 1997;29:135-40. [PMID: 8998092]
67. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J. 1988;9:777-81. [PMID: 3169046]
68. Lewis RV, Laing E, Moreland TA, Service E, McDevitt DG. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J. 1988;9:279-83. [PMID: 3289931]
69. Pomfret SM, Beasley CR, Challenor V, Holgate ST. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. Clin Sci (Lond). 1988;74:351-7. [PMID: 3281786]
70. Ahuja RC, Sinha N, Saran RK, Jain AK, Hasan M. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis-a randomised cross-over study. Int J Cardiol. 1989;25:325-31. [PMID: 2613380]
71. Botto GL, Bonini W, Broffoni T. Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil. Clin Cardiol. 1998;21:837-40. [PMID: 9825197]
72. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304-10. [PMID: 9973007]
73. Channer KS, James MA, MacConnell T, Rees JR. Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. Br J Clin Pharmacol. 1994;37:53-7. [PMID: 7908532]
74. Sweany AE, Moncloa F, Vickers FF, Zupkis RV. Antiarrhythmic effects of intravenous timolol in supraventricular arrhythmias. Clin Pharmacol Ther. 1985; 37:124-7. [PMID: 3881206]
75. DiBianco R, Morganroth J, Freitag JA, Ronan JA Jr, Lindgren KM, Donohue DJ, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J. 1984;108:1121-7. [PMID: 6148872]
76. Lawson-Matthew PJ, McLean KA, Dent M, Austin CA, Channer KS. Xamoterol improves the control of chronic atrial fibrillation in elderly patients. Age Ageing. 1995;24:321-5. [PMID: 7484490]
77. Myers J, Atwood JE, Sullivan M, Forbes S, Friis R, Pewen W, et al. Perceived exertion and gas exchange after calcium and beta-blockade in atrial fibrillation. J Appl Physiol. 1987;63:97-104. [PMID: 2887542]
78. Lin SK, Morganroth J, Heng M, Rubler S, Baird W, Atwood JE, et al. Effect of orally administered celiprolol in patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1986;8 Suppl 4:S112-5. [PMID: 2427838]
79. Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J Cardiol. 1995;52:167-74. [PMID: 8749878]
80. Wattanasuwan N, Khan IA, Mehta NJ, Arora P, Singh N, Vasavada BC, et al. Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone. Chest. 2001;119:502-6. [PMID: 11171729]
81. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med. 1997;29:135-40. [PMID: 8998092]
82. Brodsky MA, Orlov MV, Capparelli EV, Allen BJ, Iseri LT, Ginkel M, et al. Magnesium therapy in new-onset atrial fibrillation. Am J Cardiol. 1994;73: 1227-9. [PMID: 8203347]
83. Channer KS, Papouchado M, James MA, Pitcher DW, Rees JR. Towards improved control of atrial fibrillation. Eur Heart J. 1987;8:141-7. [PMID: 3552679]
84. Stern EH, Pitchon R, King BD, Guerrero J, Schneider RR, Wiener I. Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. Chest. 1982;81:308-11. [PMID: 7056105]
85. Lang R, Klein HO, Di Segni E, Gefen J, Sareli P, Libhaber C, et al. Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study. Am Heart J. 1983;105:820-5. [PMID: 6846125]
86. Zoble RG, Brewington J, Olukotun AY, Gore R. Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation. Am J Cardiol. 1987;60:39D-45D. [PMID: 3307366]
87. Smit AJ, Scaf AH, van Essen LH, Lie KI, Wesseling H. Digoxin infusion versus bolus injection in rapid atrial fibrillation: relation between serum level and response. Eur J Clin Pharmacol. 1990;38:335-41. [PMID: 2344857]
88. Hays JV, Gilman JK, Rubal BJ. Effect of magnesium sulfate on ventricular rate control in atrial fibrillation. Ann Emerg Med. 1994;24:61-4. [PMID: 8010550]
89. Roth A, Kaluski E, Felner S, Heller K, Laniado S. Clonidine for patients with rapid atrial fibrillation. Ann Intern Med. 1992;116:388-90. [PMID: 1346564]
90. Scardi S, Humar F, Pandullo C, Poletti A. Oral clonidine for heart rate control in chronic atrial fibrillation [Letter]. Lancet. 1993;341:1211-2. [PMID: 8098093]
91. Lok NS, Lau CP. Oxygen uptake kinetics and cardiopulmonary performance in lone atrial fibrillation and the effects of sotalol. Chest. 1997;111:934-40. [PMID: 9106572]
92. Boudonas G, Lefkos N, Efthymiadis AP, Styliadis IG, Tsapas G. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias. Acta Cardiol. 1995;50:125-34. [PMID: 7610735]
93. Suttorp MJ, Kingma JH, Jessurun ER, Lie-A-Huen L, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16: 1722-7. [PMID: 2123909]
94. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol. 1992;70:56A-60A. [PMID: 1510000]
95. Dahlström CG, Edvardsson N, Nasheng C, Olsson SB. Effects of diltiazem, propranolol, and their combination in the control of atrial fibrillation. Clin Cardiol. 1992;15:280-4. [PMID: 1563131]
96. Joshi PP, Deshmukh PK, Salkar RG. Efficacy of intravenous magnesium sulphate in supraventricular tachyarrhythmias. J Assoc Physicians India. 1995;43: 529-31. [PMID: 8772970]
97. Gullestad L, Birkeland K, Molstad P, Hoyer MM, Vanberg P, Kjekshus J. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol. 1993;16:429-34. [PMID: 8504578]
98. James MA, Channer KS, Papouchado M, Rees JR. Improved control of atrial fibrillation with combined pindolol and digoxin therapy. Eur Heart J. 1989; 10:83-90. [PMID: 2702970]
99. Zehender M, Hohnloser S, Müller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol. 1992; 19:1054-9. [PMID: 1552095]
100. Lee SH, Chen SA, Chiang CE, Tai CT, Wen ZC, Wang SP, et al. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med. 1996;239:253-60. [PMID: 8772625]
101. Botto GL, Capucci A, Bonini W, Boriani G, Broffoni T, Barone P, et al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. Int J Cardiol. 1997; 58:55-61. [PMID: 9021428]
102. Miller MR, McNamara RL, Segal JB, Kim N, Robinson KA, Goodman SN, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46. [PMID: 11093570]
103. Guo GB, Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by [butilide is associated with increased atrial cycle length variability. J Am Coll Cardiol. 1996;27:1083-9. [PMID: 8609325]
104. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC Jr, Meissner MC, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130-6. [PMID: 8752805]
105. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613-21. [PMID: 8840852]
106. Abi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GH, Perry KT. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study Investigators. Am Heart J. 1998; 136:632-42. [PMID: 9778066]
107. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol. 1989;63:693-6. [PMID: 2493733]
108. Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intensive Care Med. 1994;20:42-4. [PMID: 8163757]
109. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 1995;75:693-7. [PMID: 7900662]
110. Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992;70:69-72. [PMID: 1615873]
111. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol. 1997;29:385-90. [PMID: 9014993]
112. Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000;21:1265-73. [PMID: 10924317]
113. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001;104:292-6. [PMID: 11457747]
114. Lindeboom JE, Kingma JH, Crijns HJ, Dunselman PH. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. Am J Cardiol. 2000;85:1031-3. [PMID: 10760352]
115. Norgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J. 1999;137:1062-9. [PMID: 10347332]
116. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385-90. [PMID: 11067793]
117. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med. 1997;126:621-5. [PMID: 91031291
118. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest. 1995;108:355-8. [PMID: 76348661
119. Fresco C, Prodemer A, Pavan A, Buia G, Vicentini A, Pavan D, et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Clin Cardiol. 1996;19:409-12. [PMID: 8723601]
120. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol. 1997;79:418-23. [PMID: 9052343]
121. Azpitarte J, Alvarez M, Baún O, Gaxcía R, Moreno E, Martín F, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J. 1997;18:1649-54. [PMID: 9347277]
122. Bellandi F, Dabizzi RP, Cantini F, Natale MD, Niccoli L. Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation-a single-blind placebo-controlled study. Cardiovasc Drugs Ther. 1996;10:153-7. [PMID: 8842507]
123. Capucci A, Boriani G, Rubino I, Della Casa S, Sanguinetti M, Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol. 1994;43: 305-13. [PMID: 8181888]
124. Weiner P, Ganam R, Ganem R, Zidan F, Rabner M. Clinical course of recent-onset atrial fibrillation treated with oral propafenone. Chest. 1994;105: 1013-6. [PMID: 8162718]
125. Kochiadakis GE, Igoumenidis NE, Parthenakis FI, Chlouverakis GI, Vardas PE. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1999;33:966-71. [PMID: 10091823]
126. Bianconi L, Mennuni M. Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial. Am J Cardiol. 1998;82:584-8. [PMID: 9732884]
127. Ganau G, Lenzi T. Intravenous propafenone for converting recent onset atrial fibrillation in emergency departments: a randomized placebo-controlled multicenter trial. FAPS Investigators Study Group. J Emerg Med. 1998;16: 383-7. [PMID: 9610964]
128. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol. 1997;79:418-23. [PMID: 9052343]
129. Baroffio R, Tisi G, Guzzini F, Milvio E, Annoni P. A randomized study comparing digoxin and propafenone in the treatment of recent onset atrial fibrillation. Clin Drug Invest. 1995;9:277-83.
130. Kochiadakis GE, Igoumenidis NE, Simantirakis EN, Marketou ME, Parthenakis FI, Mezilis NE, et al. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. Pacing Clin Electrophysiol. 1998;21:2475-9. [PMID: 9825370]
131. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol. 1990;65:679-80. [PMID: 2178386]
132. Cowan JC, Gardiner P, Reid DS, Newell DJ, Campbell RW. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction. J Cardiovasc Pharmacol. 1986;8:252-6. [PMID: 2422461]
133. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16:521-8. [PMID: 7671898]
134. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98:2574-9. [PMID: 9843465]
135. Joseph AP, Ward MR. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med. 2000;36:1-9. [PMID: 10874228]
136. Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1998;81:995-8. [PMID: 9576159]
137. Vardas PE, Kochiadakis GE, Igoumenidis NE, Tsatsakis AM, Simantirakis EN, Chlouverakis GI. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest. 2000;117:1538-45. [PMID: 10858380]
138. Peuhkurinen K, Niemelä M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol. 2000;85:462-5. [PMID: 10728951]
139. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia-Dorado D, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079-82. [PMID: 8609324]
140. Cotter G, Blatt A, Kaluski E, Metzkor-Cotter E, Koren M, Litinski I, et al. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J. 1999;20:1833-42. [PMID: 10581142]
141. Galperín J, Elizari MV, Chiale PA, Molina RT, Ledesma R, Scapín AO, et al. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther. 2001;6:341-50. [PMID: 11907636]
142. Singh S, Saini RK, DiMarco J, Kluger J, Gold R, Chen YW. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. Am J Cardiol. 1991;68:1227-30. [PMID: 1951086]
143. Sung RJ, Tan HL, Karagounis L, Hanyok JJ, Falk R, Platia E, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. Am Heart J. 1995;129:739-48. [PMID: 7900626]
144. Baldi N, Russo VA, Lenti V, Marasco G, Polimeni G, Conserva R, et al. Relation between plasma levels and efficacy of flecainide and propafenone for treatment of atrial fibrillation of recent onset. New Trends Arrhythmias. 1993;9: 899-906.
145. Martínez-Marcos FJ, García-Garmendia JL, Ortega-Carpio A, Fernández-Gómez JM, Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000;86:950-3. [PMID: 11053705]
146. Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E, Gattermeier M, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol. 1998;81:1450-4. [PMID: 9645896]
147. Madrid AH, Moro C, Marín-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J. 1993;14:1127-31. [PMID: 8404944]
148. Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart. 1998;79:568-75. [PMID: 10078083]
149. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998;31:1414-9. [PMID: 9581743]
150. Bertini G, Conti A, Fradella G, Francardelli L, Giglioli C, Mangialavori G, et al. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med. 1990;8:15-20. [PMID: 2351794]
151. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 1995;26:852-8. [PMID: 7560608]
152. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol. 1995;76:495-8. [PMID: 7653451]
153. Roden DM. Risks and benefits of antiarthythmic therapy. N Engl J Med. 1994;331:785-91. [PMID: 8065408]
154. Falk RH. Proarthythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1992;117:141-50. [PMID: 1605429]
155. Maisel WH, Kuntz KM, Reirnold SC, Lee TH, Antman EM, Friedman PL, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 1997;127:281-4. [PMID: 9265427]
156. Prystowsky EN. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Clin Cardiol. 1994; 17:117-10. [PMID: 7882612]
157. Zimetbaum PJ, Schreckengost VE, Cohen DJ, Lemery R, Love D, Epstein LM, et al. Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. Am J Cardiol. 1999;83:450-2. [PMID: 10072241]
158. Blanc JJ, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol. 1999;84:1029-32. [PMID: 10569658]
159. Alp NJ, Bell JA, Shahi M. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart. 2000;84:37-40. [PMID: 10862585]
160. Levi G, Proto C, Rovetta A. Double-blind evaluation of practolol and quinidine in the treatment of chronic atrial fibrillation. Cardiology. 1973;58: 364-8. [PMID: 4608474]
161. Innes GD, Vertesi L, Dillon EC, Metcalfe C. Effectiveness of verapamilquinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation. Ann Emerg Med. 1997;29:126-34. [PMID: 8998091]
162. Lown B, Perlroth MG, Kaidbey S, Abe T, Harken DE. " Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients. N Engl J Med. 1963;269:325-31. [PMID: 13931297]
163. Scott ME, Geddes JS, Patterson GC. The long term prognosis of atrial fibrillation following direct current conversion. Ulster Med J. 1968;37:155-61. [PMID: 5700240]
164. McCarthy C, Varghese PJ, Barritt DW. Prognosis of atrial arrhythmias treated by electrical counter shock therapy. A three-year follow-up. Br Heart J. 1969;31:496-500. [PMID: 5791131]
165. Gunning JF, Kristinsson A, Miller G, Saunders K. Long-term follow-up of direct current cardioversion after cardiac surgery with special reference to quinidine. Br Heart J. 1970;32:462-6. [PMID: 4914821]
166. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208-16. [PMID: 4180019]
167. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344:1411-20. [PMID: 11346805]
168. Page RL, Kerber RE, Russell JK, Trouton T, Waktare J, Gallik D, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 2002;39:1956-63. [PMID: 12084594]
169. Lévy S, Lauribe P, Dolla E, Kou W, Kadish A, Calkins H, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation. 1992;86:1415-20. [PMID: 1423954]
170. Alt E, Ammer R, Schmitt C, Evans F, Lehmann G, Pasquantonio J, et al. A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion. Eur Heart J. 1997;18:1796-804. [PMID: 9402455]
171. Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation. 2000;101: 1282-7. [PMID: 10725288]
172. Niebauer MJ, Chunk MK, Wilkoff BL, Schweikert RA, Saliba WI, Jaeger FJ, et al. Success rate of the rectilinear biphasic waveform in atrial cardioversion in a large cohort of patients [Abstract]. Circulation. 2000;102:II574f.
173. Rasmussen K, Wang H, Fausa D. Comparative efficiency of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation. A controlled clinical trial. Acta Med Scand Suppl. 1981;645:23-8. [PMID: 7015799]
174. Byrne-Quinn E, Wing AJ. Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acdng quinidine bisulphate. Br Heart J. 1970;32:370-6. [PMID: 4911757]
175. Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. Br Heart J. 1971;33:518-21. [PMID: 4934041]
176. Bianconi L, Mennuni M, Luldc V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol. 1996;28:700-6. [PMID: 8772759]
177. Bianconi L, Mennuni M, Lukic V, Tassoni G, Santini M. Pretreatment with oral propafenone in electrical cardioversion of chronic atrial fibrillation. New Trends Arrhythmias. 1993;9:1017-20.
178. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, et al. Facilitadng transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 1999;340:1849-54. [PMID: 10369847]
179. Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardio-version from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J. 1995;129:71-5. [PMID: 7817928]
180. Klein AL, Murray RD, Grimm RA. Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol. 2001;37:691-704. [PMID: 11693739]
181. Goldman MJ. The management of chronic atrial fibrillation: indications for and method of conversion to normal rhythm. Progress in Cardiovascular Diseases. 1960;2:465-79.
182. Leung DY, Davidson PM, Cranney GB, Walsh WF. Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol. 1997;79:626-9. [PMID: 9068521]
183. Stöllberger C, Chnupa P, Kronik G, Brainin M, Finsterer J, Schneider B, et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. Ann Intern Med. 1998;128:630-8. [PMID: 9537936]
184. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307-16. [PMID: 8294679]
185. Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J. 1995;129:1204-15. [PMID: 7754955]
186. Harjai K, Mobarek S, Abi-Samra F, Gilliland Y, Davison N, Drake K, et al. Mechanical dysfunction of the left atrium and the left atrial appendage following cardioversion of atrial fibrillation and its relation to total electrical energy used for cardioversion. Am J Cardiol. 1998;81:1125-9. [PMID: 9605054]
187. Hirsh J, Dalen J, Guyatt G. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest. 2001;119(1 Suppl):1S-2S. [PMID: 11157638]
188. Hwang JJ, Chen JJ, Lin SC, Tseng YZ, Kuan P, Lien WP, et al. Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations. Am J Cardiol. 1993;72:677-81. [PMID: 8249844]
189. Manning WJ, Weintraub RM, Waksmonski CA, Haering JM, Rooney PS, Maslow AD, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med. 1995;123:817-22. [PMID: 7486462]
190. Fatkin D, Scalia G, Jacobs N, Burstow D, Leung D, Walsh W, et al. Accuracy of biplane transesophageal echocardiography in detecting left atrial thrombus. Am J Cardiol. 1996;77:321-3. [PMID: 8607421]
191. Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med. 1993;328:750-5. [PMID: 8437595]
192. Seidl K, Rameken M, Drögemüller A, Vater M, Brandt A, Schwacke H, et al. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study. J Am Coll Cardiol. 2002;39:1436-42. [PMID: 11985904]
193. Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation. J Am Coll Cardiol. 1997; 29:122-30. [PMID: 8996304]
194. Bellandi F, Cantini F, Pedone T, Palchetti R, Bamoshmoosh M, Dabizzi RP. Effectiveness of intravenous propafenone for conversion of recent-onset atrial fibrillation: a placebo-controlled study. Clin Cardiol. 1995;18:631-4. [PMID: 8590531]
195. Tommaso C, McDonough T, Parker M, Talano JV. Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil. Arch Intern Med. 1983;143:877-81. [PMID: 6679229]
196. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-20. [PMID: 10738049]
197. Kochiadakis GE, Marketou ME, Igoumenidis NE, Chrysostomakis SI, Mavrakis HE, Kaleboubas MD, et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm? Pacing Clin Electrophysiol. 2000;23:1883-7. [PMID: 11139949]
198. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989; 321:406-12. [PMID: 2473403]
199. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82:1106-16. [PMID: 2144796]
200. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol. 1996;77:53A-59A. [PMID: 8607392]
201. van Wijk LM, den Heijer P, Crijns HJ, van Gilst WH, Lie KI. Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol. 1989;13:32-6. [PMID: 2468933]
202. Aliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol. 1996;77: 66A-71A. [PMID: 8607394]
203. Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol. 1989;64:1317-21. [PMID: 2511744]
204. Crijns HJ, Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. Cardiovasc Drugs Ther. 1996;10:145-52. [PMID: 8842506]
205. Lee SH, Chen SA, Tai CT, Chiang CE, Wen ZC, Chen YJ, et al. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol. 1997;79:905-8. [PMID: 9104904]
206. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation. 1995;92:2550-7. [PMID: 7586356]
207. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993;71:558-63. [PMID: 8438741]
208. Bellandi F, Simonetti I, Leoncini M, Frascarelli F, Giovannini T, Maioli M, et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88:640-5. [PMID: 11564387]
209. de Paola AA, Veloso HH. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo. Am J Cardiol. 1999;84: 1033-7. [PMID: 10569659]
210. Benditt DG, Williams JH, Jin J, Deering TF, Zucker R, Browne K, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1999;84:270-7. [PMID: 10496434]
211. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932-9. [PMID: 2242519]
212. Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. J Am Coll Cardiol. 2000;36:794-802. [PMID: 10987602]
213. Södermark T, Jonsson B, Olsson A, Orö L, Wallin H, Edhag O, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. Br Heart J. 1975;37:486-92. [PMID: 1093559]
214. Bellandi F, Dabizzi RP, Niccoli L, Cantini F. Propafenone and sotalol in the prevention of paroxysmal atrial fibrillation: long-term safety and efficacy study. Current Therapeutic Research. 1995;56:1154-68.
215. Antonielli E, Pizzuti A, Pálinkás A, Tanga M, Gruber N, Michelassi C, et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2002;39:1443-9. [PMID: 11985905]